Clinical Trial Update: Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a three-drug regimen (alisertib, bortezomib, and rituximab) in patients with relapsed or refractory mantle cell lymphoma or B-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Alisertib (alisertib)
• Bortezomib (bortezomib)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING